# Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT

> **NCT03455972** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 43 (actual)

## Conditions studied

- Safety and Efficacy

## Interventions

- **BIOLOGICAL:** anti-CD19 and anti-BCMA CAR
- **DRUG:** Immunomodulatory drugs

## Key facts

- **NCT ID:** NCT03455972
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-02-20
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03455972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03455972, "Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03455972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*